Yahoo Finance Trending tickers: Nvidia, Apple, Unilever and Astrazeneca
The latest investor updates on stocks that are trending on Tuesday
Nvidia (NVDA)
Nvidia has unveiled its latest artificial intelligence (AI) chip which it said it is up to 30 times speedier than its predecessor.
Its new chip, named the Blackwell B200, takes two chips the size of Nvidia’s previous offering and binds them together into a single chip.
“Blackwell GPUs are the engine to power this new industrial revolution,” said NVIDIA CEO Jensen Huang at the company’s annual GTC event in San Jose attended by thousands of developers.
Read more: FTSE 100 LIVE: European markets cautious as central banks circle wagons on rates
“Generative AI is the defining technology of our time. Working with the most dynamic companies in the world, we will realize the promise of AI for every industry,” Huang added in a press release.
Nvidia has an 80% share of the data centre AI chip market and hopes to cement its dominance with this latest chip.
The company is the third-most valuable company in the US, behind only Microsoft (MSFT) and Apple.
Apple (AAPL)
Apple is discussing a potential deal to integrate Google’s (GOOG) artificial intelligence platform Gemini into the iPhone, Bloomberg reported.
Apple is holding “active negotiations” to license Gemini’s AI models to integrate its generative AI features into an upcoming software update to the iPhone later this year.
Apple’s models could power on-device generative AI with iOS 18, releasing later this year, while cloud-based AI features like text- and image-generation could come via partnerships with the likes of Google.
"Given Apple's installed base of 2.2 billion iOS devices, a licensing deal based on volume of usage could end up being a very significant cost for Apple but a fixed license for any cloud-based usage would not be economical for partners,” Bank of America analyst Wamsi Mohan said.
“An on-device fixed charge per device seems most likely but would be more limited in capabilities. Apple could also use this as an approach to speed up time to market, while continuing to develop in-house technologies,” he added.
Unilever (ULVR.L)
Unilever has warned that up to 7,500 jobs are at risk as the Magnum maker outlined plans to split off its ice cream unit as a separate business.
This overhaul is primarily aimed at saving around €800m (£684m) over the next three years. The plan will separate its ice cream businesses and divide the rest of Unilever into four divisions: Beauty & Wellbeing, Personal Care, Home Care and Nutrition.
The FTSE 100 consumer goods giant said it was accelerating its “growth action plan” which will make it a “simpler, more focused company”.
Matt Britzman, equity analyst at Hargreaves Lansdown, said: “Action is what shareholders wanted to see from the new team at the top, and that’s what’s been delivered today.
“Ice cream always looked like the odd one out when you compare it to other product lines, and performance has struggled of late.
Read more: AI could spark 'complete annihilation of humankind' unless regulated
“It’s not a huge shock to see this move, but it’s something prior management wasn’t able to deliver.
“Unilever’s not an overly expensive name at the minute so expect markets to react positively to the news, perhaps more due to the decisive action than anything else.”
According to the group, any impacted staff members will be consulted about the job cuts but did not reveal whereabouts they will be made.
Astrazeneca (AZN.L)
AstraZeneca has acquired oncology biotech Fusion Pharmaceuticals for $2.4bn as part of a plan to accelerate the development of next-generation cancer treatments.
Canadian biotech Fusion, whose shares trade in New York, is involved in radiopharmaceuticals, a rapidly growing area of cancer treatment that targets specific organs, tissues or cells within the human body.
"The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments," said AstraZeneca.
The deal involves a $2bn upfront cash transaction, with a total transaction value of $2.4bn based on contingent, further payments. It follows AstraZeneca’s $1bn acquisition of a French rare diseases start-up Amolyt last week.
Watch: Nvidia CEO unveils latest powerful chip at “AI Woodstock”
Download the Yahoo Finance app, available for Apple and Android.
